PCSK9 as a CVD Biomarker for cardiovascular disease
Approval of PCSK9 inhibitors as cholesterol-lowering drugs featured among the top stories in cardiology last year. Research has now ascribed another role for PCSK9 – as a biomarker for cardiovascular disease (CVD).
A study published online in the journal Circulation says that serum proprotein convertase subtilisin/kexin type 9 (PCSK9) levels predict risk of cardiovascular events even after adjustments for established CVD risk factors.
The prospective cohort study enrolled 4,232 men and women aged 60 years and who were free of CVD and showed that subjects with higher baseline serum PCSK9 levels were at a much higher risk of developing incident CVD of follow-up compared to those with the lowest levels of PCSK9. This association remained significant even after adjustment for other established CV risk factors such as hypertension, diabetes, obesity, LDL cholesterol.